EMAIL THIS PAGE TO A FRIEND

Cancer biology & therapy

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.


PMID 25869917

Abstract

PR-104 is a clinical stage bioreductive prodrug that is converted in vivo to its cognate alcohol, PR-104A. This dinitrobenzamide mustard is reduced to activated DNA cross-linking metabolites (hydroxylamine PR-104H and amine PR-104M) under hypoxia by one-electron reductases and independently of hypoxia by the 2-electron reductase aldo-keto reductase 1C3 (AKR1C3). High expression of AKR1C3, along with extensive hypoxia, suggested the potential of PR-104 for treatment of hepatocellular carcinoma (HCC). However, a phase IB trial with sorafenib demonstrated significant toxicity that was ascribed in part to reduced PR-104A clearance, likely reflecting compromised glucuronidation in patients with advanced HCC. Here, we evaluate the activity of PR-104 in HCC xenografts (HepG2, PLC/PRF/5, SNU-398, Hep3B) in mice, which do not significantly glucuronidate PR-104A. Cell line differences in sensitivity to PR-104A in vitro under aerobic conditions could be accounted for by differences in both expression of AKR1C3 (high in HepG2 and PLC/PRF/5) and sensitivity to the major active metabolite PR-104H, to which PLC/PRF/5 was relatively resistant, while hypoxic selectivity of PR-104A cytotoxicity and reductive metabolism was greatest in the low-AKR1C3 SNU-398 and Hep3B lines. Expression of AKR1C3 in HepG2 and PLC/PRF/5 xenografts was in the range seen in 21 human HCC specimens. PR-104 monotherapy elicited significant reductions in growth of Hep3B and HepG2 xenografts, and the combination with sorafenib was significantly active in all 4 xenograft models. The results suggest that better-tolerated analogs of PR-104, without a glucuronidation liability, may have the potential to exploit AKR1C3 and/or hypoxia in HCC in humans.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2500054
Anti-AKR1C3 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1406699
Anti-AKR1C3 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB1411548
Anti-AKR1C3 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
P9346
Liquified Phenol, meets USP testing specifications, ≥89.0%
C6H6O
A6229
Monoclonal Anti-AKR1C3 antibody produced in mouse, clone NP6.G6.A6, purified immunoglobulin, buffered aqueous solution
P1037
Phenol, for molecular biology
C6H6O
P5566
Phenol, BioXtra, ≥99.5% (GC)
C6H6O
328111
Phenol, unstabilized, purified by redistillation, ≥99%
C6H6O
242322
Phenol, contains hypophosphorous as stabilizer, loose crystals, ACS reagent, ≥99.0%
C6H6O
185450
Phenol, unstabilized, ReagentPlus®, ≥99%
C6H6O
77607
Phenol, BioUltra, for molecular biology, TE-saturated, ~73% (T)
C6H6O
33517
Phenol, puriss. p.a., ACS reagent, reag. Ph. Eur., 99.0-100.5%
C6H6O
16016
Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, ≥99.5% (GC), crystalline (detached)
C6H6O
16017
Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (GC)
C6H6O
16018
Phenol, ≥96.0% (calc. on dry substance, T)
C6H6O
W322318
Phenol, ≥99%
C6H6O
W322340
Phenol, natural, 97%, FG
C6H6O
P4557
Phenol solution, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, BioReagent, for molecular biology
C6H6O
P4682
Phenol solution, Saturated with 0.1 M citrate buffer, pH 4.3 ± 0.2, BioReagent, for molecular biology
C6H6O